SkyAI Inc. (SKYA) carries a Roarable Rating of D- (Sell) with 36/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
As of 2026-11-01, SkyAI Inc. (NASDAQ: SKYA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $2.93 (-0.68% 1D, market cap $126.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SKYA ranks #787 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), SKYA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $135.9M) and PYPD (PolyPid Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $113.5M). Among the 5-stock peer group, SKYA leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).
Per SKYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737995), SkyAI Inc. generated $204.1K in revenue, -$282.5M in net income, and -$11.0M in free cash flow against $269.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 11.30 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
While SKYA currently carries a cautious 36/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
Established market leader in Health Care with deep daily trading liquidity.
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.94) and Max Pain ($3.08) forces dealer call-delta covering toward $4.63.
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
SkyAI Inc. (SKYA) slipped -0.68% to $2.93, trading at 58% of its 52-week range ($0.91 – $4.41). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
Bastion Trading to Tender All of Its Shares, Pre-Funded Warrants and Stapled Warrants into SkyAI’s Amended Cash Tender Offer Bastion Trading Supports SkyAI’s Extension of the Offer to All Pre-Funded Warrants and Stapled
Bastion, a Major Stockholder of SkyAI, Agrees to Tender All of Its Shares and Warrants and Enters Into Support AgreementIncreases Number of Pre-Funded Warrants Purchased to 100% of Each Class OutstandingAdds Outstanding
One crypto treasury company just dumped its entire coin holdings while a rival keeps stacking tokens by the millions, and both moves are sending mixed signals about which asset actually has the stronger case for investor
SkyAI (NASDAQ: $SKYA), formerly Sharps Technology, has sold every SOL token it held and launched a tender offer to ...
Stocks trading well above their 50-day average volume include MNDR, NWGL, XXII, TCRT, SKYA, SHFS, GUTS, WFF, HUBC and DKI, with sharp price moves.
Based on our cash holdings as of October 16, 2026, the purchase price represents an approximately 0.95x multiple of our net asset value ("mNAV").1The Offer will expire at one minute after 11:59 p.m., New York
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on SKYA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for SKYA. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, SkyAI Inc. (SKYA) ranks #787 by composite RQD confidence (36/100, grade D-) and #630 by equity capitalization ($126.7M). Within this direct 5-issuer industry benchmark cohort, SKYA leads on earnings valuation at N/A trailing P/E, while KRMD leads on capital efficiency and profitability with -28.7% ROIC and 62.3% gross margin. KRMD currently holds the highest overall quantitative score in the immediate peer group at 48/100 (D) compared with SKYA at 36/100 (D-).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| SKYA
ACTIVE
SkyAI Inc. | D- | 36/100 | — | -30.0% | -35.0% | -0.68% | $126.7M | Benchmark Subject |
| LUNG Pulmonx Corporation | D- | 38/100 | — | 74.2% | -35.0% | +25.60% | $135.9M | /lung-vs-skya → |
| PYPD PolyPid Ltd. | E | 33/100 | — | — | -35.0% | -3.29% | $113.5M | /pypd-vs-skya → |
| APYX Apyx Medical Corporation | E | 32/100 | — | 62.5% | -28.9% | +3.07% | $113.3M | /apyx-vs-skya → |
| KRMD KORU Medical Systems Inc. | D | 48/100 | — | 62.3% | -28.7% | +0.31% | $149.1M | /krmd-vs-skya → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), SkyAI Inc. (SKYA) reported GAAP revenue of $204.1K (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$282.5M, operating cash flow of -$11.0M, and free cash flow of -$11.0M (-142.1% YoY). On the balance sheet, SKYA closed FY2025 with $269.1M in total assets against $0 in total debt (Altman Z-Score: 11.30, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $204.1K | -$282.5M | -$11.0M | -$11.0M | $269.1M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$9.3M | -$4.4M | -$4.5M | $7.3M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$9.8M | -$8.5M | -$8.5M | — | — |
As of 2026-11-01, SkyAI Inc. (NASDAQ: SKYA) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 36/100 at a spot price of $2.93 (-0.68% 1D, market cap $126.7M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, SKYA ranks #787 in composite RQD confidence.
Within the Health Care sector (Medical/Dental Instruments), SKYA carries a Roarable D- (36/100 RQD), trailing P/E of N/A, gross margin of -30.0%, and ROIC of -35.0%. By comparison, LUNG (Pulmonx Corporation) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $135.9M) and PYPD (PolyPid Ltd.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $113.5M). Among the 5-stock peer group, SKYA leads on earnings multiple (N/A) while KRMD leads on capital efficiency (-28.7% ROIC).
Per SKYA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001737995), SkyAI Inc. generated $204.1K in revenue, -$282.5M in net income, and -$11.0M in free cash flow against $269.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
SKYA last traded at $2.93 (-0.68% on volume of 605,006 shares), positioning the stock +51.03% above its 50-day simple moving average ($1.94) and +74.40% above its 200-day simple moving average ($1.68). Across its 52-week range of $0.91 to $4.41, SKYA sits at the 57.7% percentile with a 14-day RSI of 77.1 (OVERBOUGHT (>70)) and an implied next-earnings move of ±12.5% ($2.56 to $3.30).
Why SKYA Stock slipped -0.68% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
To protect compute speed and zero-delay Cboe BZX data quality for active members, our current $9.95/month Roarable Pro cohort is 100% full. Join the priority waiting list below and we will notify you the moment the next batch of Pro accounts opens (and lock in your $9.95/mo rate).
Link your personal ChatGPT, Claude Desktop, or Cursor via Roarable's Model Context Protocol (`mcp.roarable.com`) to query all 5,289 stocks, inspect Butterfly supply chains, and trade your `$100K Arena` account.
Interrogate SEC 10-K/10-Q filings on demand and ask custom ticker, valuation, or short-thesis questions directly to any of our 8 specialized AI Quant Analysts.
Command our AI agents to sort and sift 5,289 stocks by custom formulas, follow multi-indicator technical & cash-flow setups, and send you instant Email/SMS breakout & downgrade alerts.
Unlock sub-second Cboe BZX streaming quotes, pre-market/after-hours delta scanners, instant SEC Form 4 insider cluster alerts, and unlimited portfolio stress-testing.
All 8 Roarable Analysts (Mara Quenwick, Devon Kess, Gideon Vane, Eliott Vance, Sorel Thorne, Corin Hale, Tessa Rane, and Felix Orven) are proprietary AI Quant Analysts and automated algorithmic specialists — not human financial advisors, fiduciaries, or registered broker-dealers. While one-to-many daily stock ratings and briefings are free, custom 1-on-1 Q&A, custom AI sifting/indicator alert agents, and personal ChatGPT/Claude MCP connections consume dedicated per-user compute and require a $9.95/month Roarable Pro membership. All AI outputs are for educational and research purposes only and never constitute individualized investment advice.
Enter your Google email below for instant 1-step account activation, daily A–E stock rating alerts, and immediate access to your $100,000.00 Virtual Cash Arena account (100% free — no credit card required).